Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Other Non-Current Liabilities came in at $280000.0 in Q1 2026, up 8.11% YoY from $259000.0 in Q1 2025, and up 33.97% on a QoQ basis from $209000.0 in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 15 years of Other Non-Current Liabilities data on file, last reported at $280000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 8.11% year-over-year to $280000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $280000.0 (up 8.11% YoY) and the FY2025 annual result came in at $209000.0, down 33.65% from the prior year.
- Other Non-Current Liabilities grew to $280000.0 in Q1 2026, from $209000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $14.7 million in Q3 2022 to a low of $161000.0 in Q3 2025.
- A 5-year average of $4.7 million and a median of $2.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities plunged 94.22% — and 2026, when it advanced 8.11%.
- Tracing CPRX's Other Non-Current Liabilities over 5 years: stood at $14.1 million in 2022, then slumped by 78.8% to $3.0 million in 2023, then sank by 89.44% to $315000.0 in 2024, then slumped by 33.65% to $209000.0 in 2025, then jumped by 33.97% to $280000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $280000.0 (Q1 2026), $209000.0 (Q4 2025), and $161000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 280,000.00 |
| Dec 31, 2025 | 209,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 309,000.00 |
| Mar 31, 2025 | 259,000.00 |
| Dec 31, 2024 | 315,000.00 |
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Sep 30, 2023 | 3.58 Mn |
| Jun 30, 2023 | 12.72 Mn |
| Mar 31, 2023 | 13.39 Mn |
| Dec 31, 2022 | 14.06 Mn |
| Sep 30, 2022 | 14.75 Mn |
| Jun 30, 2019 | 801,264.00 |
| Dec 31, 2018 | 154,799.00 |
| Sep 30, 2018 | 164,781.00 |
| Jun 30, 2018 | 143,335.00 |
| Mar 31, 2018 | 150,395.00 |